- This topic has 0 replies, 1 voice, and was last updated 5 months, 4 weeks ago by
.
-
Posts
-
-
The medical trial, called PAX-D, investigated the effectiveness of pramipexole—a drug typically used for Parkinson’s disease—to treat treatment-resistant depression.
The article focuses on the experience of Gulliver Waite, who was diagnosed with clinical depression at age 19. After conventional treatments like antidepressants and talking therapies failed to alleviate his symptoms, he enrolled in the trial.
Key points about the trial and its outcome for Waite:
The Drug: Pramipexole mimics dopamine, which influences energy and goal-pursuit, unlike standard antidepressants that primarily target serotonin.
The Transformation: Waite reported feeling significantly better the day after starting the drug, experiencing a drastic improvement in his mood, a major increase in energy, and better sleep quality.
Long-Term Effect: Waite continued taking pramipexole after the trial and has since been off the drug, or any other antidepressants, for the longest period since his diagnosis.
Current Status: Now 31, he has more energy, an improved personal life, and was inspired by the trial to start a new job with a mental health research company.
-
